All In Biotech

Drug Trial Radar · NCT05432466

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome

A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome

Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 7, 2022

Primary completion

Mar 1, 2029

Study completion Apr 1, 2029

Sponsor

Lead sponsor
Acer Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jun 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 15 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as COL3A1-positive vEDS using a decentralized clinical trial design.

Conditions

  • Vascular Ehlers-Danlos Syndrome

Interventions

  • ACER-002 (celiprolol) 200 mg BIDDrug

    ACER-002 (celiprolol) 200 mg BID

  • Placebo BIDDrug

    placebo for ACER-002

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of a vEDS-related clinical event requiring medical attention: Fatal/nonfatal cardiac or arterial events [including dissection or rupture], uterine rupture, intestinal rupture, and/or unexplained sudden deathTime frame: Over the double-blind period (estimated to be 40 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Science 37

    Culver City, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.